AlphAIAlphAI — Financial news for AI agents
investing.com$LQDA

Liquidia shares dip despite earnings miss on strong revenue

Liquidia Corporation (LQDA) reported a Q3 loss of $2.64 per share, missing estimates, but revenue of $225.3M beat expectations. The loss included a $389.7M litigation settlement. YUTREPIA sales rose 331% YoY. Shares dipped 0.77% premarket. Cash reserves were $396.1M as of Q3. R&D and SG&A expenses increased significantly.

Original reporting
investing.com
Published Nov 10, 2026, 12:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LQDA
Bearish
high confidence
Mentioned
$LQDA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LQDABearishMed
01

Why it matters

The earnings miss and settlement charge drive short‑term downside, but strong revenue growth and cash buildup may mitigate longer‑term concerns.

02

Market read

First‑report earnings miss with a large settlement charge; modest pre‑market price impact.

03

What to watch

Cash balance rose to $396.1M, providing runway for continued commercialization and R&D.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Liquidia is a biotech firm commercializing YUTREPIA for pulmonary arterial hypertension.

Company-level read

Ticker impact

$LQDABearishHigh confidence
Context

Liquidia reported a Q3 loss of $2.64 per share and a $389.7M litigation settlement, causing a 0.77% pre‑market dip.

Expected impact

likely modest downside as the market prices in the loss and settlement charge

Evidence & confidence

The disclosed loss and settlement are new information and directly explain the pre‑market price decline.

Market effects

Sector

The biotech sector may see slight pressure as the settlement highlights litigation risk for similar companies.

Regional

Limited to U.S. small‑cap biotech investors.

Global

Minimal; impact confined to Liquidia and peers.

Counterpoint

What could challenge this read

The settlement removes future litigation risk, and YUTREPIA sales surged 331%, which could support a rebound.

Key entities

  • company
    Liquidia Corporation

    Biotech company reporting Q3 results.

  • company
    United Therapeutics

    Counterparty in the litigation settlement.

Read at source← All news

StoryLiquidia posts strong Q3 sales and adjusted EBITDA growth, but GAAP loss driven by $389.7M settlement charge

Also covered by

4 outlets

Related articles

$LQDAMedAI 8/10

Why is Liquidia stock gaining today?

Liquidia Corporation (LQDA) shares rose 1.4% in pre-market trading after reporting Q3 2026 results. Revenue of $225.3M beat estimates, driven by $222.7M in YUTREPIA sales, up 31% from the prior quarter. A $389.7M litigation charge resulted in a GAAP net loss of $2.64 per share, but operational metrics showed growth, including record patient shipments and an expanding prescriber base. The company's cash position increased to $396.1M.

investing.com
$LQDAMed

Liquidia Reports Strong Third-Quarter YUTREPIA Sales Growth

Liquidia (LQDA) reported Q3 2026 net sales of $222.7M for YUTREPIA, up 31% from Q2, with October patient shipments at a record high. The company settled litigation with United Therapeutics, incurring a $389.7M charge and a Q3 net loss of $236.3M. Non-GAAP adjusted EBITDA was $140.5M, up for the fifth consecutive quarter. Cash reserves were $396.1M at Q3's end. The FDA granted Fast Track designation to YUTREPIA for a new indication, and the company initiated two new studies.

tipranks.com
$LQDAHighAI 8/10

Liquidia Corporation Reports Third Quarter 2026 Financial Results

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 · October 2026 total patient shipments reached thei

SEC EDGAR 8-K